Tag: serplulimab
Intas launches HETRONIFLY, India’s first immunotherapy for advanced small cell lung...
Serplulimab is the first PD-1 inhibitor worldwide to receive approval for ES-SCLC, and is currently present in over 40 countries
Intas & Henlius receive positive CHMP opinion for HETRONIFLY in European...
HANSIZHUANG (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC